.Cagkan Sayin/Adobe Stock
A comparison of drugs targeted for price negotiations under recent legislation finds that currently, retail prices for those drugs are on average three times higher in the U.S. than in other high-income countries.
The findings are part of an analysis of Medicare's decision to negotiate drug prices for the program's enrollees, which will end up saving money for both enrollees and the federal agency. The study, published by the Commonwealth Fund, compared U.S. drug prices to prices in other countries, both before and after the changes. Even when those changes take effect, U.S. consumers will pay significantly higher costs when compared to consumers in those other countries, the data showed.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
